Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphoma-Reference-Cited by-同舟云学术

Characterization of immune exhaustion and suppression in the tumor microenvironment of splenic marginal zone lymphoma

Published:2023-04-28 Issue:7 Volume:37 Page:1485-1498
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Anagnostou Theodora,Yang Zhi-Zhang^ORCID,Jalali Shahrzad,Kim Hyo Jin,Larson Daniel P.^ORCID,Tang Xinyi^ORCID,Yu Yue,Pritchett Joshua C.^ORCID,Bisneto Jose Villasboas,Price-Troska Tammy L.,Mondello Patrizia,Novak Anne J.,Ansell Stephen M.^ORCID

Funder

U.S. Department of Defense

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-023-01911-2.pdf

Reference44 articles.

1. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311–9.

2. Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134:1144–53.

3. Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, et al. Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J Clin Oncol. 2019;37:481–9.

4. Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34:2698–704.

5. Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017;129:3419–27.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TIGIT: Will it be the next star therapeutic target like PD-1 in hematological malignancies?;Critical Reviews in Oncology/Hematology;2024-09

2. Voluntary exercise sensitizes cancer immunotherapy via the collagen inhibition-orchestrated inflammatory tumor immune microenvironment;Cell Reports;2024-09

3. The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications;Exploration of Targeted Anti-tumor Therapy;2024-07-23

4. Integrated spatial and multimodal single‐cell transcriptomics reveal patient‐dependent cell heterogeneity in splenic marginal zone lymphoma;The Journal of Pathology;2024-06-03

5. Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target;Blood Cancer Journal;2024-05-02